Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InnoCan Pharma ( (TSE:INNO) ) has issued an announcement.
Innocan Pharma reported a significant increase in revenues for 2024, with a 114.6% rise to $29.4 million, driven by strong sales from its subsidiary, BI Sky Global Ltd. The company’s financial performance reflects its strategic focus on innovative drug delivery technologies and its commitment to expanding its presence in the beauty and personal care industry, providing growing value to shareholders.
More about InnoCan Pharma
Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors, focusing on developing a CBD-loaded liposome drug delivery platform for non-opioid pain management. The company also markets a wide portfolio of self-care and beauty products through its subsidiary, BI Sky Global Ltd., with an emphasis on advanced online sales.
YTD Price Performance: -8.09%
Average Trading Volume: 2,320
Technical Sentiment Signal: Strong Buy
Current Market Cap: $42.11M
For detailed information about INNO stock, go to TipRanks’ Stock Analysis page.